Monthly Archives: May 2022

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors

Company achieves major milestones in clinical development programs in 2022

Patient treatment in Acclaim-2 clinical trial commences